As various smart products continue to appear in the public eye, people's attention to artificial intelligence is gradually heating up, especially the Alpha dog's victory over Li Shishi, which once caused the concept of artificial intelligence to detonate the capital market. However, for enterprises and markets, the real key question is when artificial intelligence can be used and promoted commercially, and assume the role of serving human society.
This breakthrough may be the first to appear in the medical field. According to the Securities Times reporter, Shenbo Medical recently obtained a green approval channel for the registration and approval of an artificial intelligence product, and will soon become the first medical enterprise in China to obtain the registration and approval of artificial intelligence products.
Medical treatment is one of the earliest industries to apply artificial intelligence. Its application has been 40 years old, namely computer aided diagnosis (cad). The current CAD research is mostly limited to breast and thoracic pulmonary disease, so the breast and The CAD study of pulmonary nodular lesions can basically represent the highest level and current status of CAD in medical imaging. Foreign CAD commercialization applications are concentrated in these two areas, and the most mature commercialization is breast disease examination.
The artificial intelligence product that Shenbo Medical is about to approve is the Automated Breast Volume Scanner (ABVS) system. Liu Yun, the founder of Shenbo Medical's investment side, said that ABVS is hardware, and this hardware only has artificial intelligence after docking CAD. The artificial intelligence diagnosis of ABVS+CAD, compared with the traditional core diagnosis, is that the intervention of B-ultrasound doctor is no longer needed, and the system helps to give a diagnosis.
Since it is no longer necessary to rely on the experience of traditional B-ultrasound doctors, Liu Yun said that this aspect of the hospital has greatly saved labor costs, and on the other hand, the accuracy of diagnosis has been greatly improved.
It is understood that in the international market, giant companies such as GE and Siemens have already targeted this field, and have successively launched ABVS products, and are also striving to carry out research and development on big data accumulation and artificial intelligence automatic identification of Chinese people. In the Chinese market, Shenbo Medical R&D team is the pioneer of international breast CAD commercialization and a core member of ABVS's originator U-system. GE and Siemens full-volume technology is also based on U-system. From this perspective, Chinese companies have certain competitiveness with international companies.
Liu Yun said that in the field of artificial intelligence, it is not the issue of competition at present. The most important thing is that for the screening of breast cancer in China, due to the lack of doctors in B-ultrasound and the lack of screening ability in primary hospitals, ABVS+CAD faces huge Business application opportunities. According to the National Bureau of Statistics, the total number of women aged 35 to 64 in China is 20,642,400. According to the average ultrasound screening of 120 yuan, the market for breast cancer screening for women of appropriate age will reach a market size of more than 20 billion.
Tnc Female Connector,Straight Tnc Male Connector,Tnc Male Crimp Connector,Tnc Male Coaxial Connector
Changzhou Kingsun New Energy Technology Co., Ltd. , https://www.aioconn.com